Sustainable access to effective antibiotics - what should the EU do?EPHA #A2MDialogues
15 April 2021
Continuing our successful online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
How can we solve the AMR epidemic? What is the role of the EU?
What can HERA do?
The scientific and structural difficulties in discovering new antibiotics have only begun to be appreciated in recent years, while discussions on how to overcome financial bottlenecks have gathered much attention. To overcome these scientific barriers, the public sector needs to get involved to get the highest priority antibiotics, diagnostics and vaccines developed.
We need a new alternative to the traditional patent-based business model, where the return on investment does not depend on high volume sales or high prices of novel antibiotics. Importantly, we need to have strategies in place to minimize their unnecessary use to keep them effective for as long as possible and ensure they are affordable for those in need from the onset of the development process.
Join our panel to discuss how to foster R&D of new antimicrobial therapies, diagnostics and vaccines in order to replace antibiotics rendered ineffective by AMR, reduce unnecessary use of antibiotics and prevent infections.
ReAct – Action on Antibiotic Resistance (Europe)
Public Health Consultant
Head, Drug Resistant Infections Programme
Policy Manager, Universal Access to Affordable Medicines
European Public Health Alliance
Catch up on EPHA’s other #A2MDialogues below
After COVID-19, what's next for EU medicines policies?
9 March 2021
Getting it right: Recommendations for a European BARDA
8 December 2020
The The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
Pharma & COVID19: Winners, losers, prospects
19 November 2020
The EU's IP strategy: Enabler or barrier?
27 October 2020
Unleashing meaningful innovation through regulatory reform
19 October 2020